Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) Director Gary Patou sold 4,891 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals stock traded up $1.35 during mid-day trading on Friday, hitting $41.15. The company's stock had a trading volume of 335,417 shares, compared to its average volume of 389,069. The stock has a market cap of $3.14 billion, a PE ratio of -14.69 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a one year low of $28.20 and a one year high of $50.99. The company has a 50 day moving average of $41.22 and a 200-day moving average of $40.25.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the prior year, the company earned ($0.73) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.12 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Wedbush lowered their price target on Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating for the company in a research report on Friday, August 9th. HC Wainwright reiterated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. William Blair raised Xenon Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Finally, Raymond James reaffirmed an "outperform" rating and set a $50.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $57.45.
Check Out Our Latest Stock Analysis on Xenon Pharmaceuticals
Institutional Trading of Xenon Pharmaceuticals
A number of institutional investors have recently modified their holdings of the company. Blue Trust Inc. boosted its holdings in Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 641 shares in the last quarter. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals in the 3rd quarter worth approximately $102,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after acquiring an additional 487 shares during the period. Quarry LP raised its holdings in shares of Xenon Pharmaceuticals by 207.7% during the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $156,000 after purchasing an additional 2,700 shares during the last quarter. Finally, ProShare Advisors LLC raised its position in Xenon Pharmaceuticals by 12.0% during the first quarter. ProShare Advisors LLC now owns 5,286 shares of the biopharmaceutical company's stock valued at $228,000 after acquiring an additional 565 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
